Early Detection of Lung Cancer in a High-Risk Population Defined by PFT, Biomarkers, and CT Scanning

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

531 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-11-30

Study Completion Date

2020-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Lung cancer is the number one cancer killer in Kentucky and has a very high incidence within the 5th Congressional District of Kentucky (110.8 cases per 100,000 in period 1996-2000). Surgical removal provides the best chance for cure. Unfortunately, the majority of lung cancer cases are detected in an advanced stage, when surgical resection is impossible. This leads to shorter survival rates and increased mortality rates for lung cancer, increased patient suffering, and greater cost to the healthcare system. Methods that favor earlier detection are therefore crucial for successful treatment. One such method, low-dose spiral computed tomography (CT) is being studied to determine whether its use as a screening method will lead to earlier detection and earlier intervention, perhaps impacting survival and mortality in lung cancer. This method has a modest sensitivity to detect lung cancer, but low specificity, which leads to many false positives and a low negative predictive value. The present study is designed to address both of these limitations by: 1) identifying individuals in the population at highest risk for developing lung cancer (due to smoking habits and decreased pulmonary function) for subsequent CT screening, and 2) performing biomarker testing in conjunction with the CT scan to improve the ability to discern individuals with benign lung nodules from those with malignant tumors. The 5th Congressional District of Kentucky has one of the highest rates of lung cancer in the nation and is an ideal location to test the validity (sensitivity and specificity), feasibility (negative and positive predictive value), and efficacy (stage distribution shift to earlier stage disease, increased survival, and decreased cancer-specific mortality) of these strategies to enhance early detection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Early Detection of Lung Cancer

NCT03181256

Lung Cancer

ACTIVE_NOT_RECRUITING

LC-NMR Study Biomarkers to Detect Lung Cancer

NCT02024113

Lung Cancer

COMPLETED

Lung Cancer Screening Study With Low-dose CT Scan and Blood Biomarker

NCT01700257

High Risk of Developing Lung Cancer

COMPLETED NA

Circulating Tumor DNA in Patients at High Risk for Lung Cancer

NCT02715102

Cancer of the Lung Lung Cancer Lung Neoplasms +3 more

TERMINATED

Lung Cancer Screening in Family Members and Peers of Lung Cancer Patients: a Prospective Cohort Study

NCT05645731

Lung Cancer Lung Cancer Screening Patient Empowerment

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

SCREENING

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Screening CT

Group Type EXPERIMENTAL

CT

Intervention Type OTHER

Screening CT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CT

Screening CT

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 55-75 years old.
* Identification of a primary care physician (can be identified by study staff if needed).
* FEV1/FVC \<70% (GOLD 1 or higher COPD) (poor breathing function).
* \> or = 40 pack-year current or former (within the last 10 years) tobacco use (i.e. heavy cigarette smoking history).

Exclusion Criteria

* Enrolled in any other lung screening or lung cancer prevention trial.
* Chest CT within the prior 12 months.
* Inability to lie flat with arms raised above the head.
* Current or prior personal history of lung cancer.
* Prior history of cancer within the last five years or currently receiving treatment for cancer, except adequately treated non-melanomatous skin cancer or in-situ cervical cancer.
* Life expectancy of less than 5 years.
* Patients requiring supplemental oxygen.
* Inability to give informed consent.

Minimum Eligible Age

55 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes